Table 2.
Pre- and post-propensity score matching of baseline sociodemographic and clinical characteristics of patients with prior statin therapy hospitalized due to COVID-19
| Pre-propensity matching | Post-propensity matching | |||||||
|---|---|---|---|---|---|---|---|---|
| In-hospital use of statins (n =1130) | Withdrawal of statins (n = 1791) | p value | SMD | In-hospital use of statins (n = 934) | Withdrawal of statins (n = 934) | p value | SMD | |
| Age | 74(66;81.5) | 74 (66;81.5) | 0.525 | 0.022 | 73 (65;80) | 72 (65;80) | 0.212 | 0.065 |
| Male | 679 (60.3 %) | 1077 (60.3 %) | 1 | 0.081 | 571 (61.1 %) | 580 (62.1 %) | 0.703 | 0.019 |
| Obesity | 276 (27.1 %) | 432 (26.3 %) | 0.675 | 0.018 | 249 (26.7 %) | 250 (26.8 %) | 1 | 0.002 |
| Hypertension | 698 (61.8 %) | 1144 (64 %) | 0.243 | 0.045 | 358 (38.3 %) | 353 (37.7 %) | 0.565 | 0.106 |
| Diabetes without target organ damage | 181 (16.5 %) | 314 (18 %) | 0.329 | 0.039 | 152 (16.3 %) | 165 (17.7 %) | 0.460 | 0.037 |
| Diabetes with target organ damage | 86 (7.7 %) | 168 (9.5 %) | 0.116 | 0.063 | 70 (7.4 %) | 71 (7.6 %) | 1 | 0.004 |
| Coronary artery disease | 110 (9.7 %) | 183 (10.2 %) | 0.719 | 0.016 | 97 (10.4 %) | 105 (11.2 %) | 0.602 | 0027 |
| Dyslipidemia | 677 (60 %) | 1089 (60.9 %) | 0.640 | 0.019 | 559 (59.9 %) | 567 (60.7 %) | 0.741 | 0.017 |
| Ischemic stroke | 41 (3.6 %) | 65 (3.6 %) | 1 | 0.0001 | 30 (3.21 %) | 30 (3.21 %) | 1 | 0 |
| Transient ischemic attack | 62 (5.6 %) | 113 (6.4 %) | 0.412 | 0.034 | 50 (5.35 %) | 44 (4.71 %) | 0.597 | 0.029 |
| Peripheral artery disease | 83 (7.5 %) | 124 (7.1 %) | 0.711 | 0.017 | 68 (7.28 %) | 74 (7.92 %) | 0.662 | 0.024 |
| Heart failure | 97 (8.6 %) | 129 (7.2 %) | 0.203 | 0.054 | 77 (8.24 %) | 82 (8.78 %) | 0.740 | 0.019 |
| ACEI/ARB treatment | 641 (56.9 %) | 965 (54.2 %) | 0.166 | 0.054 | 549 (58.8 %) | 550 (58.9 %) | 1 | 0.002 |
| qSOFA (high risk) | 81 (7.7 %) | 175 (10.4) | 0.022 | 0.018 | 68(7.3 %) | 62(6.6 %) | 0.657 | 0 |
| Serum creatinine(mg/dL) | 1.1 (0.7;1.2) | 1.09 (0.6;1.1) | 0.226 | 0.133 | 1.13(0.7;1.2) | 1.04(0.7;1.2) | 0.205 | 0.080 |
| C-reactive protein (mg/L) | 54 (17.2;127) | 66.7 (23;137) | 0.004 | 0.034 | 54.8(15.9;127) | 59.8 (20.8;123) | 0.403 | 0.006 |
| Lymphocyte count (x106/L) | 920 (660;1290) | 900 (670;1200) | 0.227 | 0.017 | 970(700;1300) | 977 (700;1300) | 0.795 | 0 |
| D-dimer (ng/mL) | 680 (400;1300) | 680 (380;1276) | 0.474 | 0.001 | 678 (40;1300) | 632 (350;1174) | 0.051 | 0.009 |
Comparisons were made between patients who continued to receive statins versus patients who did not continue to receive statins during hospitalization
ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, qSOFA quick sequential organ failure assessment score
Data are shown as median (interquartile range) or absolute data and percentages. A significant imbalance in the group was defined as a standardized mean difference (SMD) between baseline variables of greater than 10 %. Values were considered to be statistically significant when p < 0.05